Drug May Improve Survival for Non-Small Cell Lung Cancer Patients
This makes the news that researchers found that a drug which could offer better survival rates in NSCLC patients all the more important. The New England Journal of Medicine recently featured a study regarding nivolumab, a drug that recently completed a very promising clinical trial among 582 lung cancer patients.
The trial group consisted of patients whose cancer had progressed during or after chemotherapy treatment. To test the drug, 292 were given nivolumab while the other 290 received another medication, docetaxel. After 12 months, 51 percent of the nivolumab patients were still alive, compared with 39 percent of the docetaxel patients. The improved nivolumab survival rates continued at the 18-month mark; 29 percent were still alive compared to 23 percent in the other group.
While the researchers found survival improvement among all nivolumab patients, those with certain types of lung cancer tumors benefited the most. Patients with tumors with a particular protein known as PD-L1 (programmed death ligand 1) had a better objective response rate to the nivolumab.
Disability Benefits for Lung Cancer Patients
Lung cancer alone can cause serious impairments, and when combined with chemotherapy can leave a person unable to continue working. If this has happened to you or a loved one, you may be entitled to Social Security disability benefits.
The Disability Help Group is here to fight for your rights to disability benefits when you can no longer work and earn a living. Contact us online or call us at 1-(800)-800-3332.